ACCO Form 4: SVP McCormack Receives 1,858.7 RSUs Across 2026–2028 Vesting
Rhea-AI Filing Summary
ACCO BRANDS Corp (ACCO) reported grants of Restricted Stock Units (RSUs) to Gregory J. McCormack, SVP, Global Products & Ops. On 09/10/2025 the reporting person was awarded three RSU grants that vest on 03/14/2026 (589.4 RSUs), 03/12/2027 (618.9 RSUs) and 03/11/2028 (650.4 RSUs). Each RSU represents the right to receive one share of common stock if the reporting person remains employed through the applicable vesting date; some RSUs reflect dividend equivalent adjustments. The Form 4 is signed by an attorney-in-fact and shows these are awards, not open-market purchases or sales.
Positive
- Executive retention and alignment: multi‑year RSU grants tie the officer's compensation to future share performance and continued employment
- Staggered vesting: vesting in 2026, 2027 and 2028 spreads incentives over time, reducing single‑date turnover risk
- Dividend equivalents applied: additional RSUs from dividend equivalent provisions modestly increase awarded shares, reflecting total compensation adjustments
Negative
- Potential dilution: RSUs convert to common stock on vesting, which may increase outstanding shares if settled in shares rather than net share settlement
- Limited immediate market signal: awards are grants rather than purchases or sales, so they do not indicate insider buying conviction
Insights
TL;DR: Routine time‑based RSU grants align executive pay with shareholder outcomes without immediate share dilution.
The reported grants are standard time‑based restricted stock units under the issuer's incentive plan, subject to continued employment and potential acceleration per plan terms. These awards increase the executive's stake over multi‑year vesting horizons, providing retention incentives. The filing discloses dividend equivalent credits applied to existing awards, which modestly increases settled shares. No sales or option exercises were reported, indicating no immediate change in free‑float from insider dispositions.
TL;DR: Grants total 1,858.7 RSUs across three vesting dates, representing deferred equity compensation rather than cash pay.
Summing the awards yields 1,858.7 RSUs delivered via grant and dividend equivalents on 09/10/2025. Vesting across 2026–2028 staggers potential equity issuance and aligns long‑term incentives with performance/retention. The filing lacks dollar valuation beyond a $0 exercise price because RSUs convert to shares; investors should note these convert to common stock on vesting, which increases outstanding shares over time if not net‑settled.